Search research articles
Contact Us
Filters
Showing results (91-100 of 148) with videos related to
Page
of 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 22, 2021
Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort
S Schrodi, M Braun, A Andrulat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2020
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
S Dent, J Cortés, Y-H Im, et al.
ESMO Open
|
December 4, 2024
Surface-based deep inspiration breath-hold radiotherapy in left-sided breast cancer: final results from the SAVE-HEART study
S Schönecker, L Angelini, A Gaasch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2023
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
N Harbeck, P A Fasching, R Wuerstlein, et al.
ESMO Open
|
December 22, 2024
HER2DX genomic test in early-stage HER2-positive breast cancer
S M Tolaney, N Tung, A C Wolff, et al.
Breast (Edinburgh, Scotland)
|
August 25, 2011
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
J Huober, P A Fasching, M Barsoum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
V Möbus, C Jackisch, H J Lück, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 5, 2008
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
O Gluz, U A Nitz, N Harbeck, et al.
Breast Cancer Research and Treatment
|
January 12, 2019
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H S Rugo, R S Finn, V Diéras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
V Möbus, G von Minckwitz, C Jackisch, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 148) with videos related to
Sort By:
Page
of 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 22, 2021
Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort
S Schrodi, M Braun, A Andrulat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2020
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
S Dent, J Cortés, Y-H Im, et al.
ESMO Open
|
December 4, 2024
Surface-based deep inspiration breath-hold radiotherapy in left-sided breast cancer: final results from the SAVE-HEART study
S Schönecker, L Angelini, A Gaasch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2023
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
N Harbeck, P A Fasching, R Wuerstlein, et al.
ESMO Open
|
December 22, 2024
HER2DX genomic test in early-stage HER2-positive breast cancer
S M Tolaney, N Tung, A C Wolff, et al.
Breast (Edinburgh, Scotland)
|
August 25, 2011
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
J Huober, P A Fasching, M Barsoum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
V Möbus, C Jackisch, H J Lück, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 5, 2008
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
O Gluz, U A Nitz, N Harbeck, et al.
Breast Cancer Research and Treatment
|
January 12, 2019
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H S Rugo, R S Finn, V Diéras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
V Möbus, G von Minckwitz, C Jackisch, et al.
Page
of 15